Literature DB >> 15899893

Crystal structure of acetylcholine-binding protein from Bulinus truncatus reveals the conserved structural scaffold and sites of variation in nicotinic acetylcholine receptors.

Patrick H N Celie1, Remco V Klaassen, Sarah E van Rossum-Fikkert, René van Elk, Pim van Nierop, August B Smit, Titia K Sixma.   

Abstract

The crystal structure of acetylcholine-binding protein (AChBP) from the mollusk Lymnaea stagnalis is the established model for the ligand binding domains of the ligand-gated ion channel family, which includes nicotinic acetylcholine, 5-hydroxytryptamine (5-HT3), gamma-aminobutyric acid (GABA), types A and C, and glycine receptors. Here we present the crystal structure of a remote homolog, AChBP from Bulinus truncatus, which reveals both the conserved structural scaffold and the sites of variation in this receptor family. These include rigid body movements of loops that are close to the transmembrane interface in the receptors and changes in the intermonomer contacts, which alter the pentamer stability drastically. Structural, pharmacological and mutational analysis of both AChBPs shows how 3 amino acid changes in the binding site contribute to a 5-10-fold difference in affinity for nicotinic ligands. Comparison of these structures will be valuable for improving structure-function studies of ligand-gated ion channel receptors, including signal transduction, homology modeling, and drug design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899893     DOI: 10.1074/jbc.M414476200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  74 in total

Review 1.  Synaptic neurotransmitter-gated receptors.

Authors:  Trevor G Smart; Pierre Paoletti
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

2.  Enhanced meta-analysis of acetylcholine binding protein structures reveals conformational signatures of agonism in nicotinic receptors.

Authors:  Spencer T Stober; Cameron F Abrams
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

3.  Virtual screening against acetylcholine binding protein.

Authors:  Maleeruk Utsintong; Piyanuch Rojsanga; Kwok-Yiu Ho; Todd T Talley; Arthur J Olson; Kinzo Matsumoto; Opa Vajragupta
Journal:  J Biomol Screen       Date:  2011-09-28

Review 4.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

5.  Unbinding pathways of an agonist and an antagonist from the 5-HT3 receptor.

Authors:  A J Thompson; P-L Chau; S L Chan; S C R Lummis
Journal:  Biophys J       Date:  2005-12-30       Impact factor: 4.033

6.  The intronic GABRG2 mutation, IVS6+2T->G, associated with childhood absence epilepsy altered subunit mRNA intron splicing, activated nonsense-mediated decay, and produced a stable truncated γ2 subunit.

Authors:  Mengnan Tian; Robert L Macdonald
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

Review 7.  The neurobiologist's guide to structural biology: a primer on why macromolecular structure matters and how to evaluate structural data.

Authors:  Daniel L Minor
Journal:  Neuron       Date:  2007-05-24       Impact factor: 17.173

Review 8.  Allosteric activation mechanism of the cys-loop receptors.

Authors:  Yong-chang Chang; Wen Wu; Jian-liang Zhang; Yao Huang
Journal:  Acta Pharmacol Sin       Date:  2009-05-11       Impact factor: 6.150

9.  Single-channel current through nicotinic receptor produced by closure of binding site C-loop.

Authors:  Hai-Long Wang; Reza Toghraee; David Papke; Xiao-Lin Cheng; J Andrew McCammon; Umberto Ravaioli; Steven M Sine
Journal:  Biophys J       Date:  2009-05-06       Impact factor: 4.033

Review 10.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.